Edwards Lifesciences Corporation $EW Stock: Sivik Global Healthcare LLC Raises Position

Sivik Global Healthcare LLC boosted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 125.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,000 shares of the medical research company’s stock after buying an additional 25,000 shares during the quarter. Edwards Lifesciences makes up approximately 2.4% of Sivik Global Healthcare LLC’s portfolio, making the stock its 18th largest holding. Sivik Global Healthcare LLC’s holdings in Edwards Lifesciences were worth $3,884,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Pin Oak Investment Advisors Inc. acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter worth $26,000. TrinityBridge Ltd purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at about $27,000. GK Wealth Management LLC acquired a new stake in Edwards Lifesciences during the third quarter worth about $26,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences during the fourth quarter worth about $26,000. Finally, Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences in the 1st quarter valued at about $25,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on EW. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $87.00 to $101.00 in a report on Friday, July 24th. Barclays upgraded Edwards Lifesciences to a “strong-buy” rating in a report on Wednesday, October 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Piper Sandler reissued an “overweight” rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Trading Down 0.8%

Shares of NYSE:EW traded down $0.70 during mid-day trading on Tuesday, reaching $85.69. 977,864 shares of the company were exchanged, compared to its average volume of 4,496,346. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The firm has a market cap of $49.34 billion, a price-to-earnings ratio of 49.24, a P/E/G ratio of 2.23 and a beta of 0.87. The firm’s 50-day simple moving average is $88.67 and its 200 day simple moving average is $86.22. Edwards Lifesciences Corporation has a 1 year low of $72.40 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the previous year, the company earned $0.67 earnings per share. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 3.00 EPS for the current year.

Insiders Place Their Bets

In related news, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 5,045 shares of company stock worth $451,596 over the last three months. Company insiders own 0.31% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.